Heart Disease: Page 2

Who stands to gain from polygenic risk scoring for heart disease?

The retrospective study evaluated the value of polygenic risk scores (PRSs) in a total of 47,108 middle-aged people (mean, 60 years) treated at hospitals affiliated with three different U.S. institutions on the East Coast: Partners HealthCare (MA), the University of Pennsylvania Health System (PA), and the Mount Sinai Health System (NY).

June 9, 2020

American College of Cardiology paves way for return of diagnostics

The pandemic has restricted routine medical care, including invasive procedures to treat heart disease and diagnostic tests to diagnose it, the ACC said. Delays in this care can increase patients' risk of adverse outcomes, according to the college.

May 4, 2020

Could a 5th 'vital sign' curb the spread of COVID-19?

A typical patient evaluation includes an assessment of temperature, heart rate, respiratory rate, and blood pressure. But in the context of COVID-19, adding travel history is key, wrote a research pair led by Dr. Trish Perl, chief of the division of infectious diseases at the University of Texas Southwestern Medical Center.

March 2, 2020

Genetic risk scoring not ready for prime time in heart disease

One study evaluated risk scoring in a cohort of participants in UK Biobank, a nonprofit research project that is performing whole genome sequencing on a mass scale in the U.K. The observational study assessed polygenic risk scores, pooled cohort equations (risk prediction models), and both combined for predicting events in 352,660 participants with no cardiovascular disease at baseline.

February 18, 2020

Blood test spots diabetes complications early on

The development is significant for patients with type 2 diabetes because if vascular complications, such as heart disease, atherosclerosis, or kidney failure, are detected at an early stage, preventive treatments could be given to avoid severe clinical outcomes down the line.

October 1, 2019

Cardiologists back more screening, tight LDL and glucose control

Screening involves testing for a high level of low-density lipoprotein cholesterol (LDL-C) and identifying a history of early personal and/or familial heart disease. The diagnosis can be confirmed with a genetic test that is widely available in Europe, the ESC noted in a statement about the research at the meeting, held jointly with the World Heart Federation's WCC from August 31 to September 4 in Paris.

September 2, 2019